Clarivate guided FY 2026 revenue including discontinued ops to USD 2.3 billion-USD 2.42 billion, with the midpoint at about USD 2.35 billion.
Organic ACV growth outlook set at 0.75%-2.25%, flagged for the lower half as Life Sciences & Healthcare shifts to discontinued ops in H2.
Recurring organic revenue growth forecast at (4)% to 3%, with expectations for H2 acceleration on subscription growth and re-occurring revenue recovery.
Adjusted EBITDA expected at about USD 980 million-USD 1.04 billion, with adjusted EBITDA margin at 42%-43.5%.
Adjusted diluted EPS outlook at $0.7-$0.8; free cash flow expected at USD 365 million-USD 435 million, pressured by one-time transaction and cost-savings charges.
CLVT•
